东曜药业(1875.HK)获评“年度卓越生物医药企业”，生态创新价值持续获认可

Core Viewpoint - Dongyao Pharmaceutical (1875.HK) has been awarded the "Annual Outstanding Biopharmaceutical Company" for its continuous innovation and stable growth in the biopharmaceutical sector, reflecting market recognition of its unique development path and platform value [1][3]. Group 1: Company Achievements - The "Annual Outstanding Biopharmaceutical Company" award focuses on R&D innovation capability, core product competitiveness, commercialization progress, and sustainable development potential, recognizing companies that create long-term value for the industry and investors [3]. - Dongyao Pharmaceutical has established a differentiated ADC (Antibody-Drug Conjugate) technology platform, creating a competitive barrier and becoming one of the few global CDMO service companies with a full industry chain for ADCs [4][5]. Group 2: Strategic Positioning - The company has strategically focused on the ADC sector, which has high technical barriers and broad market prospects, successfully building an integrated platform covering R&D, process development, clinical trials, regulatory approval, and commercial production [4][5]. - Dongyao's platform ecosystem enhances its competitive advantage by collaborating with various domestic and international pharmaceutical companies, creating a virtuous cycle of internal R&D and external service empowerment [5]. Group 3: Financial Performance - Dongyao Pharmaceutical has translated its strategic positioning into tangible financial performance, with its commercialized product, Puxintin® (Bevacizumab Injection), expanding globally and providing stable cash flow [7]. - The CDMO business, particularly in the ADC field, has seen a continuous increase in orders, contributing to revenue growth and optimizing the company's overall profit model, with 16 new projects added by mid-2025, including 14 ADC projects [8]. Group 4: Future Outlook - The recognition of Dongyao Pharmaceutical as an outstanding biopharmaceutical company underscores the market's affirmation of its ADC technology platform and full industry chain capabilities [10]. - The company's development path illustrates that true excellence in the biopharmaceutical industry requires not only cutting-edge scientific insights but also the ability to convert technological advantages into sustainable commercialization and platform ecosystems [10].